DMRA
Income statement / Annual
Last year (2025), Damora Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Damora Therapeutics Inc.'s net income was -$209.84 M.
See Damora Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$181.00 K
|
$830.00 K
|
$490.00 K
|
$441.00 K
|
$188.00 K
|
$111.00 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$181.00 K
|
-$830.00 K
|
-$490.00 K
|
-$441.00 K
|
-$188.00 K
|
-$111.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$201.19 M
|
$6.40 M
|
$23.77 M
|
$48.21 M
|
$38.49 M
|
$24.63 M
|
$36.53 M
|
$10.09 M
|
| General & Administrative Expenses |
$9.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.69 M
|
$10.32 M
|
$11.86 M
|
$12.51 M
|
$13.30 M
|
$8.82 M
|
$2.33 M
|
$2.81 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$210.87 M
|
$16.72 M
|
$35.63 M
|
$60.72 M
|
$51.79 M
|
$33.45 M
|
$38.86 M
|
$12.91 M
|
| Cost And Expenses |
$210.87 M
|
$16.90 M
|
$36.46 M
|
$61.21 M
|
$52.23 M
|
$33.64 M
|
$38.97 M
|
$12.91 M
|
| Interest Income |
$1.17 M
|
$844.00 K
|
$1.69 M
|
$722.00 K
|
$156.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.97 M
|
| Depreciation & Amortization |
$34.00 K
|
$181.00 K
|
$830.00 K
|
$490.00 K
|
$441.00 K
|
$188.00 K
|
$111.00 K
|
$0.00
|
| EBITDA |
-$209.76 M |
-$21.22 M |
-$37.52 M |
-$61.13 M |
-$51.31 M |
-$33.45 M |
-$38.86 M |
-$12.91 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.08 M
|
-$4.50 M
|
-$1.89 M
|
-$417.00 K
|
$475.00 K
|
-$1.20 M
|
$2.46 M
|
-$2.96 M
|
| Income Before Tax |
-$209.79 M
|
-$21.40 M
|
-$38.35 M
|
-$61.62 M
|
-$51.75 M
|
-$34.84 M
|
-$36.51 M
|
-$15.87 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$50.00 K
|
$41.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$209.84 M
|
-$21.44 M
|
-$38.35 M
|
-$61.62 M
|
-$51.75 M
|
-$34.84 M
|
-$36.51 M
|
-$15.87 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-158.13 |
-18.53 |
-36.08 |
-60.63 |
-51.22 |
-34.48 |
-41.35 |
-18.68 |
| EPS Diluted |
-158.13 |
-18.53 |
-36.08 |
-60.63 |
-51.22 |
-34.48 |
-41.35 |
-18.68 |
| Weighted Average Shares Out |
$1.33 M
|
$1.16 M
|
$1.06 M
|
$1.02 M
|
$1.01 M
|
$1.01 M
|
$1.02 M
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$1.33 M
|
$1.16 M
|
$1.06 M
|
$1.02 M
|
$1.01 M
|
$1.01 M
|
$1.02 M
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
|
